| | | × | | | | | | | | | | | | |
|---|--|---|------------------|------------------------------|---|---|------|--|---|-------------|--|------------|---|--|
| Substitute for form 1449/PTO (Revised 07/2005) INFORMATION DISCLOSURE | | | | | | Complete if Known | | | | | | | | |
| | | | | | Α | Application Number | | | 10/577,672 | | | | | |
| | | | | | F | Filing Date | | | November 20, 2006 | | | | | |
| | | | | | F | First Named Inventor | | | Long | | | | | |
| | | | | | G | Group Art Unit | | | 1644 | | | | | |
| STATEMENT BY APPLICANT | | | | | | | | | | | , | | | |
| (Use as many sheets as necessary) | | | | | | Examiner Name | | | To Be Assigned | | | | | |
| Sheet | 1 | 1 of 1 | | | | Attorney Docket Number | | | 035784/311261 | | | | | |
| | | | | | | | | | | | | | | |
| | | | | U | . S. | PATENT D | oct | JMENT | ΓS | | | | | |
| | Document Number | | | | | | | | | | | | | |
| Examiner Initials* | No. Number - Kind Code (if known) | | | | Name of Patentee or | | | . | Pages, Columns, Lines, Where Relevant Passages of Relevant Figures | | | | | |
| minais. | NO. | Number - Kind Code (if known) | | | IVII | MM-DD-YYYY | | Applicant of Cited Document | | it | Appear | | | |
| | | | | | | | | | | | | | | |
| | L | | | · | l | | | | | | | | | |
| | | | | FOR | REIC | SN PATENT | DC | CUMI | ENTS | | | | | |
| | | Foreign Patent Document | | | | | | | | | Pages, Columns, | | English | |
| Examiner Initials | Cite No. | Country Code - Number Kind Code (if known) | | | | Publication Date MM-DD-YYY | | Name of Patentee or Applicant of Cited Document | | | Relevant Passages T | | Language | |
| | | | | | de | | | | | nent | | | Translation Attached | |
| | | | | | | | | | | | | | Attached | |
| | 7 | WO 02/04021 A1 | | | | 01.15.0000 | | YDTG DI | | , | | | | |
| | 7 | WO 02/04021 A1 | | | | 01-17-2002 | | IDEC Pharmaceuticals | | .is | | | | |
| | | | | | | | | Corporation | | | | | | |
| | 8 | WO 02/22212 A2 | | | | 03-21-2002 | | IDEC Pharmaceuticals | | | | | | |
| | | | | | | | | Corporation | | | | | | |
| | 9 | WO 03/029296 A1 | | | | | | China Camanatia | | | ······································ | | | |
| | 9 | W U U3/U29290 A1 | | | | 04-10-2003 | | Chiron Corporation | | | | , | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | - | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | 7 | | | | | | |
| | L | | | | | l | | <u> </u> | | | | | <u> </u> | |
| | | | | | \mathbf{O} | THER DOC | UM | ENTS | | | | | | |
| | | Inch | do nomo of the | author (in CA | DITA | I I ETTEDO\ 4 | | C 41 | 1. (.1 | \t | 6.4 | Engli | ish Language | |
| | | item | (hook magazir | aumor (m.CA e iournal ser | PITAL LETTERS), title of the article (when appropriate), title of the ial, symposium, catalog, etc.), date, page(s), volumeissue number(s), | | | | | | | ranslation | | |
| Examiner | Cite | publi | sher, city and/c | or country whe | re pu | s, symposium, catalog, etc.), date, page(s), volumeissue number(s published. | | | | | | 1 | Attached | |
| Initials* | publisher, city and/or country where published. | | | | | | | | | | | | | |
| | 10 | FUN | NAKOSHI, S | S., et al., "D | iffer | ential In Vitr | o an | d <i>In Vi</i> | vo Antitumor E | ffects | | | | |
| | | | | | | | | | | | | | | |
| 1.044441111 | | Mediated by Anti-CD40 and Anti-CD20 Monoclonal Antibodies Against Human B-Cell Lymphomas," <i>Journal of Immunology</i> , 1996, Vol. 19, No. 2, pp. 93-101. | | | | | | | | | | | | |
| | 11 | | | | | | | | | | | | *************************************** | |
| | MALONEY, D.G., et al., "IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in | | | | | | | | | | | | | |
| Patients with Relapsed Non-Hodgkin's Lymphoma," <i>Journal of Clinical Oncology</i> , 1997, Vol. 15, No. 10, pp. 3266-3274. | | | | | | | | | | | | | | |
| Dynamic | | 177 | 1, VOI. 13, N | io. 10, pp. 3 | 200 | -34/4. | | T T | | · · · · · · | | | | |
| Examiner | | | | | | | | | Date | | | | | |
| Signature | | | | | | | | | Considered | | | | | |

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.